Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Craig Meagher"'
Autor:
Min Zhu, Kara Olson, Jessica R. Kirshner, Masood Khaksar Toroghi, Hong Yan, Lauric Haber, Craig Meagher, Dina M. Flink, Srikanth R. Ambati, John D. Davis, A. Thomas DiCioccio, Eric J. Smith, Marc W. Retter
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 4, Pp 954-966 (2022)
Abstract Odronextamab is a fully‐human IgG4‐based CD20xCD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering T‐cell‐mediated cytotoxicity independent of T‐cell‐receptor recognition. Adequate safety, tolerabi
Externí odkaz:
https://doaj.org/article/a445f9bfc75148d9ba23acb3770e8acf
Autor:
Charles G. Drake, James B. Trager, Mark W. Frohlich, James B. Whitmore, Todd DeVries, Tuyen Vu, Kate Bailey, Thomas A. Gardner, Eric J. Small, Celestia S. Higano, Philip W. Kantoff, Simon J. Hall, T. Craig Meagher, Harini Kandadi, Li-Qun Fan, Nadeem A. Sheikh, Debraj GuhaThakurta
Supplementary materials and Methods, Tables ST1-13. Table ST1: Baseline clinical characteristics of patients in IMPACT Table ST2: Baseline clinical characteristics of patients in ProACT. Table ST3: Increase in levels of IgG against candidate antigens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::650c52205386cf2c8f487248d2e2a261
https://doi.org/10.1158/1078-0432.22457397
https://doi.org/10.1158/1078-0432.22457397
Autor:
Charles G. Drake, James B. Trager, Mark W. Frohlich, James B. Whitmore, Todd DeVries, Tuyen Vu, Kate Bailey, Thomas A. Gardner, Eric J. Small, Celestia S. Higano, Philip W. Kantoff, Simon J. Hall, T. Craig Meagher, Harini Kandadi, Li-Qun Fan, Nadeem A. Sheikh, Debraj GuhaThakurta
Supplementary Figure SF1. Schematic of sipuleucel-T treatment doses (infusions) and serum collection time points in IMPACT and ProACT.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c5a956c5483f5c4c7a39f5710ad783a
https://doi.org/10.1158/1078-0432.22458014
https://doi.org/10.1158/1078-0432.22458014
Autor:
Charles G. Drake, James B. Trager, Mark W. Frohlich, James B. Whitmore, Todd DeVries, Tuyen Vu, Kate Bailey, Thomas A. Gardner, Eric J. Small, Celestia S. Higano, Philip W. Kantoff, Simon J. Hall, T. Craig Meagher, Harini Kandadi, Li-Qun Fan, Nadeem A. Sheikh, Debraj GuhaThakurta
Purpose: Antitumor activity of cancer immunotherapies may elicit immune responses to nontargeted (secondary) tumor antigens, or antigen spread. We evaluated humoral antigen spread after treatment with sipuleucel-T, an immunotherapy for asymptomatic o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35ba1800e2e3b537feec9ec1ebe9dba1
https://doi.org/10.1158/1078-0432.c.6523569.v1
https://doi.org/10.1158/1078-0432.c.6523569.v1
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc02043c6c98f7aa2d395bc506f9dcc5
https://doi.org/10.1136/jitc-2022-sitc2022.1415
https://doi.org/10.1136/jitc-2022-sitc2022.1415
Autor:
Michael J. Moore, Maggie Zhong, Johanna Hansen, Hans Gartner, Craig Grant, Mei Huang, Faith M. Harris, Naxin Tu, Natalie A. Bowerman, Kurt H. Edelmann, Thomas Barry, Olivier Herbin, Chin-Siean Tay, David J. DiLillo, Corinne E. Decker, Natasha Levenkova, James Shevchuk, Ankur Dhanik, Karoline A. Meagher, Amanda Karr, Jan Roos, Wen-yi Lee, David Suh, Mark Eckersdorff, T. Craig Meagher, Matthew Koss, Lakeisha Esau, Matthew A. Sleeman, Robert Babb, Gang Chen, Christos A. Kyratsous, William T. Poueymirou, John R. McWhirter, Vera A. Voronina, Chunguang Guo, Cagan Gurer, George D. Yancopoulos, Andrew J. Murphy, Lynn E. Macdonald
Publikováno v:
Science Immunology. 6
Despite the enormous promise of T cell therapies, the isolation and study of human T cell receptors (TCRs) of dedicated specificity remains a major challenge. To overcome this limitation, we generated mice with a genetically humanized system of T cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5b33325698a8f3396e20dc96afc9308
https://doi.org/10.1126/sciimmunol.abj4026
https://doi.org/10.1126/sciimmunol.abj4026
Autor:
Min Zhu, Kara Olson, Jessica R. Kirshner, Masood Khaksar Toroghi, Hong Yan, Lauric Haber, Craig Meagher, Dina M. Flink, Srikanth R. Ambati, John D. Davis, A. Thomas DiCioccio, Eric J. Smith, Marc W. Retter
Publikováno v:
Clinical and translational science. 15(4)
Odronextamab is a fully-human IgG4-based CD20xCD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering T-cell-mediated cytotoxicity independent of T-cell-receptor recognition. Adequate safety, tolerability, and encouraging
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43e4f49640cf6d953b90535316e8e592
https://pubmed.ncbi.nlm.nih.gov/34997701
https://pubmed.ncbi.nlm.nih.gov/34997701
Autor:
Lauric Haber, ryan McKay, jennifer Finney, stephen castaneda, kristen spitler, sahar Rizvi, aidan Hwang, kevin Bray, willy Ramos, pamela Krueger, frank delfino, Craig Meagher, tammy huang, yang shen, william olson, john Lin, eric smith
Publikováno v:
Cancer Research. 82:1084-1084
Bispecific antibodies engineered to recruit T cells as a means to kill tumor cells are a promising new class of therapeutics in the field of oncology. A challenge for this class of agents is the requirement for cell surface expressed tumor specific t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8eae64f576ab62bffeb23c677611b6fb
https://doi.org/10.1158/1538-7445.am2022-1084
https://doi.org/10.1158/1538-7445.am2022-1084
Publikováno v:
Expert Review of Clinical Pharmacology. 6:387-401
Immunotherapies are coming to the forefront as a treatment paradigm in cancer with multiple US FDA approvals in recent years and a better understanding of their therapeutic mode of action. The control of tumor growth by the immune system is orchestra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::560cdbd14655a2cd77aa7dce54140be7
https://doi.org/10.1586/17512433.2013.811814
https://doi.org/10.1586/17512433.2013.811814
Autor:
Bray Kevin A, Katja Mohrs, Olin Gavin Thurston, Kara Olson, Thomas Startz, Marc W. Retter, John C. Lin, T. Craig Meagher, Olga Sineshchekova, Frank Delfino, Jessica R. Kirshner, Stephen Godin, Dilillo David, Eric Smith
Publikováno v:
Blood. 132:1944-1944
Improving therapies for multiple myeloma (MM) remains a high medical need because of the significant morbidity and mortality of the disease. Targeted immunotherapies represent a promising opportunity to fill this clinical need. B cell maturation anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a78f6d33885ec70554928a22bba0dfbd
https://doi.org/10.1182/blood-2018-99-112500
https://doi.org/10.1182/blood-2018-99-112500